The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results Article Conference Paper uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Lymph Node Excision
  • Neoplasms, Germ Cell and Embryonal
  • Retroperitoneal Neoplasms
  • Testicular Neoplasms

abstract

  • While the pathologic staging of tumors following ADT treatment was improved compared with surgical controls, to date the PSA disease-free survival rates are similar. Patients with residual extracapsular (P3) disease after ADT manifest an increased PSA failure rate compared with those with P3 tumors treated by surgery alone. This suggests that ADT may identify a subset of patients with aggressive tumors that may be candidates for additional therapeutic interventions even before PSA failure occurs.

publication date

  • March 1997

Research

keywords

  • Conference Paper

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0090-4295(97)00169-6

PubMed ID

  • 9123736

Additional Document Info

start page

  • 46

end page

  • 55

volume

  • 49

number

  • 3 SUPPL.